Suppr超能文献

个人:坦索罗辛用于下尿路症状的安慰剂对照、随机单病例试验的可行性研究方案。

PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms.

作者信息

Bauer Scott R, Breyer Benjamin N, Oni-Orisan Akinyemi, Steinman Michael A, Sim Ida, McCulloch Charles E, Kenfield Stacey A

机构信息

Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, United States.

Department of Urology, University of California, San Francisco, San Francisco, CA, United States.

出版信息

Front Digit Health. 2020 Jun 26;2:7. doi: 10.3389/fdgth.2020.00007. eCollection 2020.

Abstract

Lower urinary tract symptoms (LUTS) affect more than half of men over age 70 and contribute to both poor health-related quality of life and polypharmacy. Tamsulosin hydrochloride, a selective α-blocker, is the most common medication used to treat LUTS due to presumed benign prostatic hyperplasia and is often prescribed indefinitely, although not all men benefit from long-term therapy. N-of-1 trials allow for individualized estimates of benefit and harm and could facilitate decisions regarding chronic tamsulosin therapy for LUTS, particularly among older men. Our team developed the PERSONAL (PlacEbo-controlled, Randomized, patient-Selected Outcomes, N-of-1 triALs) app to track daily urinary symptoms and medication side effects for n-of-1 trials among older men with LUTS. We will conduct a feasibility study of 20 individual randomized n-of-1 trials using the PERSONAL app to compare tamsulosin (0.4 or 0.8 mg) vs. placebo among older men taking tamsulosin for LUTS. We will include men over age 65 with a smartphone for whom temporary discontinuation of tamsulosin is safe, (e.g., no history of acute retention). Participants will work with research staff to prospectively identify the most important urinary symptoms and medication side effects that they would like to digitally track. Men will then be randomized to 2-week treatment periods of tamsulosin or placebo followed by a 1-week wash-out with placebo, for 4 distinct treatment periods and 3 wash-out periods, totaling 11 weeks. Study medications will be blinded using over-encapsulation of tamsulosin pills and matching placebo. Our primary outcomes for this study will be recruitment and retention of eligible men, completion rates of n-of-1 trials and daily questionnaires using the PERSONAL app, and participants' perceived usefulness of their n-of-1 trial for determining whether tamsulosin is effective for them. Linear mixed effects models with individual-specific intercepts and intervention effects will also be used to estimate within-individual effects of tamsulosin. The goal of this innovative study is to establish feasibility and acceptability of using a mobile health app and n-of-1 trials to provide older men with individualized estimates of benefits and harms of chronic tamsulosin therapy for LUTS.

摘要

下尿路症状(LUTS)影响着超过半数的70岁以上男性,导致健康相关生活质量下降,并引发多种药物联合使用的情况。盐酸坦索罗辛是一种选择性α受体阻滞剂,由于推测其可治疗良性前列腺增生,因此是治疗LUTS最常用的药物,并且常常被无限期地开出处方,尽管并非所有男性都能从长期治疗中获益。单病例试验能够对获益和危害进行个体化评估,并有助于就LUTS慢性坦索罗辛治疗做出决策,尤其是在老年男性中。我们的团队开发了PERSONAL(安慰剂对照、随机、患者选择结局、单病例试验)应用程序,用于跟踪患有LUTS的老年男性单病例试验中的每日泌尿症状和药物副作用。我们将使用PERSONAL应用程序对20项个体随机单病例试验进行可行性研究,以比较坦索罗辛(0.4或0.8毫克)与安慰剂在服用坦索罗辛治疗LUTS的老年男性中的效果。我们将纳入65岁以上且拥有智能手机、暂时停用坦索罗辛安全的男性(例如,无急性尿潴留病史)。参与者将与研究人员合作,前瞻性地确定他们希望进行数字跟踪的最重要的泌尿症状和药物副作用。然后,男性将被随机分配到坦索罗辛或安慰剂的2周治疗期,随后是1周的安慰剂洗脱期,共4个不同的治疗期和3个洗脱期,总计11周。研究药物将通过对坦索罗辛药丸进行外包装并匹配安慰剂来实现盲法。本研究的主要结局将是符合条件男性的招募和留存率、使用PERSONAL应用程序的单病例试验和每日问卷的完成率,以及参与者对其单病例试验在确定坦索罗辛对他们是否有效的感知有用性。具有个体特异性截距和干预效应的线性混合效应模型也将用于估计坦索罗辛的个体内效应。这项创新研究的目标是确定使用移动健康应用程序和单病例试验为老年男性提供LUTS慢性坦索罗辛治疗获益和危害的个体化评估的可行性和可接受性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a297/8521798/68897ff2e266/fdgth-02-00007-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验